CTOs on the Move


 
Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir`s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug currently in a Phase 1/2 clinical trial for hematologic and solid tumors.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cyteir.com
  • 128 Spring Street Building A, Suite 510
    Lexington, MA USA 02421
  • Phone: 857.285.4140

Executives

Name Title Contact Details

Funding

Cyteir raised $29M on 03/08/2018
Cyteir raised $40.2M on 10/15/2019
Cyteir raised $80M on 02/11/2021

Similar Companies

Nystrom & Associates

Nystrom & Associates Here at Nystrom & Associates, we know that you want to feel confident and excited about life. Were here to help!

Boc Sciences

Boc Sciences is a Shirley, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MaxThera

MaxThera, Inc. is a Beverly, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Resau Medisca Network

Resau Medisca Network Inc. is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hemarus

Hemarus is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.